FDA medical devices
Doctors get a new federal lane for traction tools
FDA says the device can help pull tissue out of the way during endoscopic procedures, making dissections easier to see and manage. The new classification takes effect June 22, 2026.
The agency put the device into class II with special controls covering performance testing, sterility, shelf life and training. FDA says that should support access without lowering safety standards.
- FDA put endoscopic traction devices in class II.
- Special controls cover testing, sterility, labeling and training.
- The order takes effect June 22, 2026.
- FDA says the change could ease access to the device.
- In Washington, the Food and Drug Administration has put the endoscopic traction device into class II under 21 CFR, the Code of Federal Regulations, part 876, the gastroenterology-urology device category
In Washington, the Food and Drug Administration has put the endoscopic traction device into class II under 21 CFR, the Code of Federal Regulations, part 876, the gastroenterology-urology device category. The final order takes effect June 22, 2026.
For patients who need endoscopic gastrointestinal or urology care, the practical effect is a clearer federal path for a tool that helps doctors retract tissue and keep the dissection plane in view.
A tool built for close work
An endoscopic traction device is used during gastrointestinal dissection procedures to improve visibility, help with tissue resection and make removal and exposure easier. In plain English, it is meant to help doctors work more cleanly in a tight space.
FDA says the special controls attached to the classification cover performance testing, usability, sterility, biocompatibility, shelf-life data and labeling that spells out training and safe-use limits.
Safety rules, less red tape
The agency says class II is enough to provide reasonable assurance of safety and effectiveness. It also says the new category should improve patients' access to beneficial innovative devices by reducing regulatory burdens.
For manufacturers, that means a more defined route to market without dropping the safety bar the federal government still expects devices to clear.